Zhang Qian, Wang Yue, Chen Aiwen, Huang Xinwei, Dong Qianyu, Li Zhen, Gao Xiaofei, Wu Tingmei, Li Wanrong, Cong Peilin, Wan Hanxi, Dai Danqing, He Mengfan, Liang Huazheng, Wang Shaoshi, Xiong Lize
Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Clinical Research Center for Anesthesiology and Perioperative Medicine, Tongji University, Shanghai, China.
Front Pharmacol. 2021 Dec 14;12:802381. doi: 10.3389/fphar.2021.802381. eCollection 2021.
Xiaoxuming decoction (XXMD) has been traditionally used to manage stroke though debates on its clinical efficacy were present in the history. Till nowadays, it is still one of the most commonly used herbal recipes for stroke. One of the reasons is that a decent proportion of ischemic stroke patients still have residue symptoms even after thrombolysis with rt-PA or endovascular thrombectomy. Numerous clinical studies have shown that XXMD is an effective alternative therapy not only at the acute stage, but also at the chronic sequelae stage of ischemic stroke. Modern techniques have isolated groups of compounds from XXMD which have shown therapeutic effects, such as dilating blood vessels, inhibiting thrombosis, suppressing oxidative stress, attenuating nitric oxide induced damage, protecting the blood brain barrier and the neurovascular unit. However, which of the active compounds is responsible for its therapeutic effects is still unknown. Emerging studies have screened and tested these active compounds aiming to find individual compounds that can be used as drugs to treat stroke. The present study summarized both clinical evidence of XXMD in managing stroke and experimental evidence on its molecular mechanisms that have been reported recently using advanced techniques. A new perspective has also been discussed with an aim to provide new targets that can be used for screening active compounds from XXMD.
消栓明汤(XXMD)传统上一直用于治疗中风,尽管历史上对于其临床疗效存在争议。直到如今,它仍是治疗中风最常用的中药方剂之一。原因之一是,相当一部分缺血性中风患者即使在接受rt-PA溶栓或血管内取栓治疗后仍有残留症状。大量临床研究表明,消栓明汤不仅在缺血性中风的急性期,而且在慢性后遗症期都是一种有效的替代疗法。现代技术已从消栓明汤中分离出具有治疗作用的化合物组,如扩张血管、抑制血栓形成、抑制氧化应激、减轻一氧化氮诱导的损伤、保护血脑屏障和神经血管单元。然而,哪种活性化合物对其治疗作用负责仍不清楚。新兴研究对这些活性化合物进行了筛选和测试,旨在找到可作为治疗中风药物的单一化合物。本研究总结了消栓明汤治疗中风的临床证据以及最近使用先进技术报道的其分子机制的实验证据。还讨论了一个新的观点,旨在提供可用于从消栓明汤中筛选活性化合物的新靶点。